At a glance
ClinicalIndex Comparison Record- ✓VAS pain score between 40 and 95
- ✓Daily pain for at least 12 weeks
- ✓Pain catastrophizing scale score ≤30
- ✓BMI less than 40 kg/m²
- ✕Second or third-degree AV heart block, AV dissociation, or history of ventricular tachycardia
- ✕Procedure within past 6 months for permanent sensory loss (e.g., ablation)
- ✕Surgery planned during study
- ✕Acute, serious, or unstable medical condition that would preclude participation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
3 articles- STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreSTAT News·2026-06-08
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugSTAT News·2026-06-07
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugSTAT News·2026-06-06
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
In Brief
A Phase 2 clinical trial evaluating LY3016859 ISA, LY3556050 ISA, and 4 other interventions for Osteoarthritis, Knee and 2 related conditions. Currently recruiting, targeting 10,000 participants across 64 sites in 2 countries.
Detailed Summary
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Study Details
Timeline
Interventions
Administered intravenously (IV)
Administered orally
Administered orally
Administered orally
Placebo administered orally
Placebo administered IV